Fig. 1 · Structure

Documents & Downloads

FRAX597

Cat. No. A12553 CAS 1286739-19-2

PAK inhibitor

FRAX597, a small-molecule pyridopyrimidinone, is a potent and ATP competitive inhibitor of the group I PAKs (PAK1 IC50= 8 nM, PAK2 IC50= 13 nM, PAK3 IC50= 19 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FRAX597 is a group I PAK inhibitor. In the original characterization, which depicts the compound as a hydrochloride, biochemical IC50 values were 8, 13 and 19 nM for PAK1, PAK2 and PAK3, respectively, and >10 μM for PAK4. Kinase profiling also detected inhibition of YES1, RET, CSF1R and TEK, limiting its use as a PAK1-specific probe. These published values do not establish the potency of a particular catalog lot. [1]

A 2 Å crystal structure places the FRAX597 ligand in the ATP-binding pocket of the PAK1 kinase domain. The structural construct contains the K299R mutation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PAK1 8 nM
PAK2 13 nM
PAK2 13 nM
PAK3 19 nM

FRAX597 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of FRAX597 from 2 published references. In vitro models include recombinant PAK1 kinase domain, residues 249–545, K299R mutant.

FRAX597 In Vitro Studies

FRAX597 inhibited proliferation across five pancreatic cancer cell lines, with reported IC50 values of 0.65–2.0 μM by thymidine incorporation. These are proliferation endpoints rather than biochemical kinase potencies or direct measures of cell killing; the tested salt form was not specified. [2]

Biochemical potency and kinase selectivity

Biochemical assay · Recombinant PAK1, PAK2, PAK3 and PAK4; 106-kinase profiling panel [1]

FRAX597 inhibited group I PAKs at nanomolar concentrations in the reported enzyme assay. Profiling also identified inhibition of YES1, RET, CSF1R and TEK; it is not a PAK1-only probe.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAK1 enzymatic inhibitionIC50 8 nM[1]
PAK2 enzymatic inhibitionIC50 13 nM[1]
PAK3 enzymatic inhibitionIC50 19 nM[1]
PAK4 enzymatic inhibitionIC50 >10 μM[1]
Inhibition at 100 nM FRAX597Percent inhibition YES1 87%; RET 82%; CSF1R 91%; TEK 87%[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 concentration points for enzyme IC50; 100 nM for kinase panel
Method
Functional kinase inhibition assays
Reported limits
Exact ATP concentration, concentration series and vehicle for the Z′-LYTE IC50 assay are not specified in the inspected article. The separate KinaseGlo mutant experiment uses different conditions; those are not assigned here.
Methods and source locations

Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597; hydrochloride depicted in Figure 1B

Published FRAX597 parent pharmacology with tested hydrochloride depiction; these are not measured potencies for an Adooq free-base lot. No salt conversion made.

Figure 1B–C; Results: Discovery and Characterization; Experimental Procedures: Determination of Enzyme IC50 Values

PAK1 enzymatic inhibition: 10-point Z′-LYTE fluorescence coupled-enzyme assay; duplicate concentration points — Results: Discovery and Characterization; Figure 1C (7.7 nM label, rounded to 8 nM in text)

PAK2 enzymatic inhibition: Same reported enzyme assay — Results: Discovery and Characterization; Figure 1C (12.8 nM label, rounded to 13 nM in text)

PAK3 enzymatic inhibition: Same reported enzyme assay — Results: Discovery and Characterization; Figure 1C (19.3 nM label, rounded to 19 nM in text)

PAK4 enzymatic inhibition: Same reported enzyme assay — Figure 1C and Results: Discovery and Characterization

Inhibition at 100 nM FRAX597: Reported recombinant kinase panel; kinase selectivity Methods name Z′-LYTE and Adapta formats — Results: Discovery and Characterization (panel values reported as data not shown)

FRAX597 binding in the PAK1 ATP pocket

Biochemical assay · Recombinant PAK1 kinase domain, residues 249–545, K299R mutant [1]

The reported 2 Å crystal structure places FRAX597 in the PAK1 ATP-binding pocket. The crystallographic construct contains the K299R substitution, which limits direct extrapolation of detailed interactions to native PAK1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAK1–FRAX597 complexX-ray resolution 2 Å[1]
FRAX597 localizationBinding-site observation ATP-binding pocket[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM FRAX597 for crystal soaking
Exposure duration
Overnight soaking
Method
Soaking apo-PAK1 crystals with FRAX597
Reported limits
Soak concentration is a crystallographic condition, not an IC50 or cellular treatment dose. Counterion in bound structure is not asserted.
Methods and source locations

Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597 ligand; study depicts starting compound as hydrochloride in Figure 1B

Binding-site evidence for the FRAX597 parent in a recombinant mutant kinase; not a measurement on the catalog lot.

Figure 2A–B; Results: Structure of PAK1 in Complex with FRAX597; Experimental Procedures: PAK1 Structure Determination

PAK1–FRAX597 complex: X-ray crystallography; PDB 4EQC — Results: Structure of PAK1 in Complex with FRAX597; Figure 2

FRAX597 localization: Complex structure and ligand difference electron density — Figure 2A–B and accompanying Results

Pancreatic cancer cell proliferation response

Cell-based study · Human PANC-1, MiaPaCa-2, BxPC-3 and murine Pan02, LM-P pancreatic cancer cells [2]

FRAX597 reduced thymidine incorporation in concentration-response experiments. The IC50 values are cellular proliferation endpoints and do not measure PAK enzyme potency or establish cell killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PANC-1 proliferationIC50 (mean ± SEM) 2.0 ± 0.2 μM[2]
MiaPaCa-2 proliferationIC50 (mean ± SEM) 1.4 ± 0.4 μM[2]
BxPC-3 proliferationIC50 (mean ± SEM) 0.65 ± 0.1 μM[2]
Pan02 proliferationIC50 (mean ± SEM) 1.4 ± 0.1 μM[2]
LM-P proliferationIC50 (mean ± SEM) 1.1 ± 0.2 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration response shown in Figure 4a; IC50 values are endpoints, not selected treatment doses
Method
3H-thymidine incorporation; untreated cells normalized to 100%
Reported limits
Proliferation exposure duration and drug vehicle are not specified in the inspected Methods/Figure 4 caption; Methods refer to a prior protocol, not retrieved. The 24 h serum-free survival condition is not assigned to proliferation.
Methods and source locations

Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597 purchased from SYNthesis (Parkville, Australia); salt form not stated

Named FRAX597 literature evidence; applicability is at parent-compound level, with tested salt unspecified.

Figure 4a and caption; Table 2; Methods: Cells and reagents; Cell proliferation, cell survival and combination index; Statistical analysis

PANC-1 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis

MiaPaCa-2 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis

BxPC-3 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis

Pan02 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis

LM-P proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis

FRAX597 In Vivo Studies

In an orthotopic Pan02 pancreatic tumor model, FRAX597 alone at 3 mg/kg intraperitoneally every other day did not reduce tumor volume versus saline control. Combining this regimen with gemcitabine at 40 mg/kg twice weekly reduced endpoint tumor volume further than gemcitabine alone. Drug formulation vehicles were not specified. [2]

FRAX597 alone and with gemcitabine in Pan02 tumors

Animal study · C57/Bl6 mice bearing orthotopic Pan02 tumors in the pancreatic tail; 28 mice, 7 randomized per group [2]

At the 30-day endpoint, FRAX597 monotherapy did not change tumor volume compared with control. Gemcitabine reduced tumor volume; the combination produced a further significant reduction compared with gemcitabine alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume at 30 daysBetween-group comparison No difference: FRAX597 alone versus control; combination lower than gemcitabine alone (p < 0.05)[2]

Conditions shared by the study groups

Route
Intraperitoneal
Treatment course
30-day tumor-volume endpoint; precise dosing start not specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline control—Reference tumor-volume group[2]
FRAX597 alone
3 mg/kg FRAX597
Saline controlNo difference in tumor volume versus control[2]
Gemcitabine alone
40 mg/kg gemcitabine
Saline controlSignificantly lower tumor volume than saline or FRAX597 alone[2]
FRAX597 plus gemcitabine
FRAX597 3 mg/kg plus gemcitabine 40 mg/kg
Saline, FRAX597 alone and gemcitabine aloneLower tumor volume than gemcitabine alone (p < 0.05)[2]
Saline control
Model: Pan02 pancreatic-tail orthotopic tumors; 7 mice/group
Frequency: Every other day
Vehicle: Saline
FRAX597 alone
Model: Pan02 pancreatic-tail orthotopic tumors; 7 mice/group
Frequency: Every other day
Reported limits: Drug vehicle not specified.
Gemcitabine alone
Model: Pan02 pancreatic-tail orthotopic tumors; 7 mice/group
Frequency: Twice weekly
Reported limits: Drug vehicle not specified.
FRAX597 plus gemcitabine
Model: Pan02 pancreatic-tail orthotopic tumors; 7 mice/group
Frequency: FRAX597 every other day; gemcitabine twice weekly
Reported limits: Drug vehicle not specified.
Methods and source locations

Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597 purchased from SYNthesis; salt form not stated

Model- and regimen-specific monotherapy and combination evidence, with unreported FRAX597 salt and vehicle. No general in-vivo efficacy or survival claim.

Figure 7a and caption; Results: FRAX597 and gemcitabine inhibit pancreatic tumour growth in an orthotopic murine model; Methods: Murine orthotopic pancreatic cancer model

Tumor volume at 30 days: Endpoint micro-caliper measurement, ellipsoid volume calculation; mean ± SEM; 7 mice/group — Figure 7a; Methods: Murine orthotopic pancreatic cancer model; Results: orthotopic murine model

Saline control · Methods: Murine orthotopic pancreatic cancer model; Figure 7a and caption; corresponding Results

FRAX597 alone · Methods: Murine orthotopic pancreatic cancer model; Figure 7a and caption; corresponding Results

Gemcitabine alone · Methods: Murine orthotopic pancreatic cancer model; Figure 7a and caption; corresponding Results

FRAX597 plus gemcitabine · Methods: Murine orthotopic pancreatic cancer model; Figure 7a and caption; corresponding Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1286739-19-2
Applications PAK inhibitor
Formula C29H28ClN7OS
Molecular Weight 558.1
SMILES
CCN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=C(C=C3)C4=CN=CS4)Cl)NC5=CC=C(C=C5)N6CCN(CC6)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 13 mg/mL (23.29 mM)
Water Insoluble
Ethanol 1 mg/mL (1.79 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FRAX597 Research References

  1. [1] Licciulli S, Maksimoska J, Zhou C, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas Journal of Biological Chemistry (2013). PMID: 23960073 DOI: 10.1074/jbc.M113.510933 Source material
  2. [2] Yeo D, He H, Patel O, et al. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine BMC Cancer (2016). PMID: 26774265 DOI: 10.1186/s12885-016-2057-z Source material

Publications

1 publication citing this product

Added to your cart

View Cart Checkout
Loading...